About Myelomax

Founded in 2010 Myelomax is a spin-off of the Multiple Myeloma Nantes Academic Group established by INSERM (the French National Research Institute) and the University of Nantes. Emmanuelle Ménoret PhD heads up the preclinical research organization which includes leading cancer researchers and specialists on its scientific advisory board. Myelomax continues to work alongside researchers and clinicians at a world-renowned myeloma cancer center. And importantly is currently working to bring more proprietary cell lines to market so expanding its unique collection and understanding of this highly heterogeneous and still incurable disease.

Myelomax is the only preclinical CRO wholly dedicated to Multiple Myeloma worldwide and has accumulated over 5 years dedicated experience in Multiple Myeloma preclinical research with over 1600 assay tests to date against 34 molecules. Our database includes results of assays conducted on today’s current standard of care agents in 38 cell lines that are representative of heterogeneity of this cancer.

We are experts in human myeloma cell line testing and evaluation both in-vitro and in vivo. Unlike other generalist or non-specialist preclinical CROs, this means we are well placed to provide unique advice on which cell lines are the most appropriate for your study.

Meet the Myelomax team

Dr Emmanuelle Ménoret
CEO & Founding Partner

Emmanuelle Ménoret obtained her PhD in Molecular and Cellular Biology from the University of Nantes in 2009 focusing on Multiple Myeloma and Mcl-1. Identifying an opportunity in the marketplace for human myeloma cell line testing services, Emmanuelle went straight on from her doctorate to create Myelomax.

Dr Martine Amiot
Founding Partner & Scientific Advisor
Martine Amiot obtained her PhD from the Technology University of Compiegne in 1986. Martine is currently CNRS Research Director (French National Center for Scientific Research) at the Nantes-Angers Regional Cancer Research Center (CRCNA) where she heads up a multidisciplinary team of 12 people in basic research and clinical aspects working on Multiple Myeloma.With 30 years of committed research into Multiple Myeloma, and 98 papers on various aspects of Multiple Myeloma published to date, Martine has recently been received the prestigious “Palmes de Medicine 2015” award which
recognizes advances in medical research in towards finding medicines of the future. Read more about this groundbreaking research

Pr Régis Bataille
Founding Partner & Scientific Advisor
World renowned researcher in the field of Multiple Myeloma, founding member and first coordinator of the Intergroupe Français du Myélome (French Myeloma Working Group), Pr Bataille is currently completing his 5 year tenure as Director of the Paul Papin Regional Anti-Cancer Center in Angers.

Dr Charlotte Kervoëlen
Laboratory Manager

Charlotte joined the Myelomax team in 2012 as a PhD student in collaboration with the Nantes-Angers Regional Cancer Research Center (CRCNA) and studied Dexamethasone in Multiple Myeloma. She obtained her PhD in Molecular and Cellular Biology from the University of Nantes in 2015 and now manages the Myelomax laboratory.

Dr Catherine Pellat-Deceunynck
Founding Partner & Scientific Advisor
Catherine Pellat-Deceunynck obtained her PhD in Molecular and Cellular Biology from Paris X University in 1992. Catherine has published 88 papers as part of her work as a CNRS Research Scientist (French National Center for Scientific Research) at the Nantes-Angers Regional Cancer Research Center (CRCNA) working on Multiple Myeloma.

Pr Jean-Luc Harousseau
Silent Founding Partner
Pr Harousseau was Professor of Hematology at the University of Nantes where he went on to become Head of the Department of Clinical Hematology for 24 years. He held positions as Director of the Cancer Center René Gauducheau (Nantes, France) and President of the French National Health Authority from 2011 to 2016. In 2005 he received the Waldenström Award and in 2009 the Robert Kyle Lifetime Achievement Award for his scientific contribution in the field of Multiple Myeloma.

Myelomax helps pharmaceutical and biotech companies, and academic researchers in the battle to bring more effective drugs to market.

Get a quote for in-vitro and in-vivo Multiple Myeloma testing and evaluation services.